A report presented Thursday at the Clinical Trials in Alzheimer’s Disease meeting in Madrid stated that researchers found that when a transcranial magnetic stimulation, or TMS, device was aimed at the right spot in the brain, it could slow the development of Alzheimer’s Disease symptoms, such as memory loss, compared to an inactive treatment, Linda Carroll and Mustafa Fattah report for NBC News. The new study, a phase 2 clinical trial, included 32 volunteers with Alzheimer’s disease, aged 56 to 88 at the start of the study, who were followed for 52 weeks, the report noted. Dr. Giacomo Koch, a professor of human physiology at the University of Ferrara and one of the co-founders of Sinaptica, the Cambridge, Massachusetts-based company currently developing the therapy, is currently planning a phase 3 trial, which would be needed for Food and Drug Administration approval.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BWAY:
- BrainsWay Expands Deep TMS Reach in East Asia
- Brainsway announces further expansion in East Asia with 15 new systems
- BrainsWay Schedules Crucial Shareholders Meeting
- BrainsWay Secures $20M Investment from Valor Equity
- Brainsway announces $20M private placement with Valor Equity Partners
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
